Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

APOKYN

APOMORPHINE HYDROCHLORIDE

Standard Dose
20MG/2ML (10MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview APOKYN is listed in Drugs@FDA under application 021264 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient APOMORPHINE HYDROCHLORIDE Form and strength INJECTABLE;SUBCUTANEOUS - 20MG/2ML (10MG/ML) Sponsor MDD US Submission history Latest submission status date: 2025-02-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview APOKYN is listed in Drugs@FDA under application 021264 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient APOMORPHINE HYDROCHLORIDE Form and strength INJECTABLE;SUBCUTANEOUS - 20MG/2ML (10MG/ML) Sponsor MDD US Submission history Latest submission status date: 2025-02-03 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.